Speciality: Oncology
Description:
Dr. Sushant Mittal kicked off the insightful session titled "CNS Clarity from Day One: Rethinking Early Diagnostic Strategies", joined by esteemed panelists Dr. Tarachand Gupta and Dr. Randeep Singh. The discussion opened with a strong emphasis on the clinical importance of early evaluation for central nervous system (CNS) involvement, especially in complex or aggressive disease presentations. Dr. Mittal highlighted how delays in CNS assessment can result in mismanagement or missed therapeutic windows, setting the tone for a thought-provoking exchange. Dr. Gupta and Dr. Singh added their expertise from neurology and oncology perspectives, offering valuable multidisciplinary insights.
The session explored how CNS evaluation at the time of initial diagnosis is gaining traction in clinical protocols. With advancements in neuroimaging, cerebrospinal fluid analysis, and molecular biomarkers, early detection of CNS disease has become more achievable and actionable. The panel discussed real-world challenges in integrating these strategies, including resource constraints and variability in presentation. Emphasis was placed on identifying high-risk patients early - particularly in oncology and infectious disease contexts - where CNS involvement can significantly affect prognosis and treatment pathways. The conversation also touched on the need for standardized screening protocols and decision-making frameworks that support clinicians across specialties.
Thank you to all who joined this informative session. Your engagement and curiosity continue to drive these meaningful conversations forward. Special thanks to Dr. Sushant Mittal, Dr. Tarachand Gupta, and Dr. Randeep Singh for sharing their expertise. Keep following us for more sessions focused on innovation, interdisciplinary practice, and cutting-edge strategies in healthcare. Together, we’re reshaping how diseases are diagnosed and managed - starting from day one.
See More Webinars @ Hidoc Webinars
1.
Doctors say lung cancer is still the deadliest cancer, but hope is growing
2.
Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.
3.
FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.
4.
The FDA has approved momelotinib for use in myelofibrosis patients who also have anemia.
5.
Virtual Reality Travel Reduces Cancer Pain.
1.
Clinical Decision-Making in Oligometastatic Cancer: A Case-Based Perspective
2.
Iron Homeostasis Throughout the Female Lifespan
3.
The Benefits and Side Effects of Vidaza Syndrome
4.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
5.
Exercise Rehabilitation in Hematologic Disease Survivorship
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
3.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
4.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
Preventing Blood Clots: The Importance of Venous Thromboembolism Management
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation